Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 18, 2023 11:37am

111 Views

Post# 35546097

RE:RE:Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A

July 18, 2023 - " The Federal Trade Commission has requested additional information on Pfizer’s proposed acquisition of Seagen, the cancer-focused biotech revealed in a Securities and Exchange Commission filing posted Friday.

In the SEC document, Seagen disclosed that the FTC’s request will further extend the waiting period, as mandated by the Hart-Scott-Rodino Antitrust Improvements Acts of 1976, by 30 days after both Pfizer and Seagen have turned over the additional information."

https://www.biospace.com/article/ftc-digs-deeper-into-pfizer-s-43b-buyout-of-seagen/

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China